{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:11:08Z","timestamp":1770739868381,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102433","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:23:17Z","timestamp":1757517797000},"page":"102433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone Health and Body Composition as Predictive and Prognostic Markers in Metastatic Castration-resistant Prostate Cancer: A Meet-URO Narrative Review"],"prefix":"10.1016","volume":"23","author":[{"given":"Anna Amela","family":"Valsecchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102433_bib0001","unstructured":"I numeri del cancro in Italia, AIOM 2024. Accessed September 27, 2025. Available at: https:\/\/www.aiom.it\/i-numeri-del-cancro-in-italia\/."},{"issue":"7","key":"10.1016\/j.clgc.2025.102433_bib0002","doi-asserted-by":"crossref","first-page":"103484","DOI":"10.1016\/j.esmoop.2024.103484","article-title":"Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies in eng","volume":"9","author":"Cursano","year":"2024","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.clgc.2025.102433_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"issue":"3 Suppl 1","key":"10.1016\/j.clgc.2025.102433_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","article-title":"Osteoporosis during androgen deprivation therapy for prostate cancer","volume":"60","author":"Smith","year":"2002","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.clgc.2025.102433_bib0005","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.eururo.2012.11.013","article-title":"Obesity and prostate cancer: weighing the evidence","volume":"63","author":"Allott","year":"2013","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102433_bib0006","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","article-title":"The obesity paradox in cancer: a review","volume":"18","author":"Lennon","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.clgc.2025.102433_bib0007","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00345-007-0178-3","article-title":"The impact of obesity on prostate cancer","volume":"25","author":"van Roermund","year":"2007","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102433_bib0008","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MOU.0000000000000885","article-title":"The prognostic value of sarcopenia in patients with prostate cancer: a systematic review","volume":"31","author":"Jahrreiss","year":"2021","journal-title":"Curr Opin Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102433_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/raon-2024-0011","article-title":"Sarcopenic obesity in cancer","volume":"58","author":"Jurdana","year":"2024","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.clgc.2025.102433_bib0010","unstructured":"Linee guida AIOM, 2024. Metastasi ossee e salute dell'osso, Available at: https:\/\/www.aiom.it\/linee-guida-aiom-2024-metastasi-ossee-e-salute-dellosso\/. Accessed March 3, 2025."},{"issue":"3","key":"10.1016\/j.clgc.2025.102433_bib0011","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.clgc.2025.102433_bib0012","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102433_bib0013","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1507\/endocrj.45.97","article-title":"Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis","volume":"45","author":"Akimoto","year":"1998","journal-title":"Endocr J"},{"issue":"5","key":"10.1016\/j.clgc.2025.102433_bib0014","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/jpm13050705","article-title":"Biomarkers for prostate cancer bone metastasis detection and prediction","volume":"13","author":"Ying","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.clgc.2025.102433_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0009-8981(03)00081-0","article-title":"Bone remodeling markers in the detection of bone metastases in prostate cancer","volume":"331","author":"De la Piedra","year":"2003","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.clgc.2025.102433_bib0016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","article-title":"Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer","volume":"68","author":"Fizazi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102433_bib0017","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.20314","article-title":"Comparison of 10 se-rum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implica-tions","volume":"111","author":"Jung","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2025.102433_bib0018","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.juro.2007.05.029","article-title":"Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach","volume":"178","author":"Koopmans","year":"2007","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102433_bib0019","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1464-410x.2001.00105.x","article-title":"The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone","volume":"87","author":"Koizumi","year":"2001","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.clgc.2025.102433_bib0020","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.21037\/tau-20-1120","article-title":"Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases","volume":"10","author":"Aufderklamm","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102433_bib0021","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20203531","article-title":"Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis","volume":"41","author":"Yu","year":"2021","journal-title":"Biosci Rep"},{"key":"10.1016\/j.clgc.2025.102433_bib0022","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/bjc.2012.345","article-title":"Plasma osteopontin as a biomarker of prostate cancer aggression: Relationship to risk category and treatment response","volume":"107","author":"Thoms","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2025.102433_bib0023","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10585-004-2869-0","article-title":"The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft","volume":"21","author":"Kiefer","year":"2004","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"10.1016\/j.clgc.2025.102433_bib0024","doi-asserted-by":"crossref","first-page":"dju013","DOI":"10.1093\/jnci\/dju013","article-title":"Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421","volume":"106","author":"Lara","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2025.102433_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/clinchem\/43.1.85","article-title":"Bone sialoprotein in serum of patients with malignant bone diseases","volume":"43","author":"Withold","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.clgc.2025.102433_bib0026","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1158\/1078-0432.CCR-09-0783","article-title":"Small integrin-binding proteins as serum markers for prostate cancer detection","volume":"15","author":"Jain","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clgc.2025.102433_bib0027","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/annonc\/mdq037","article-title":"Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer","volume":"21","author":"Rajpar","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102433_bib0028","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102433_bib0029","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-024-01155-w","article-title":"Biomarkers of bone metabolism in [(223)Ra] RaCl(2) therapy - association with extent of disease and prediction of overall survival","volume":"14","author":"Fosb\u00f8l","year":"2024","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clgc.2025.102433_bib0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1442-2042.2008.02029.x","article-title":"Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer","volume":"15","author":"Ozu","year":"2008","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102433_bib0031","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/00045632211003941","article-title":"Biological sources of variations of tartrate-resistant acid phosphatase 5b in a healthy Japanese population","volume":"58","author":"Kikuchi","year":"2021","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.clgc.2025.102433_bib0032","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.urology.2009.11.049","article-title":"Implications of serum bone turnover markers in prostate cancer patients with bone metastasis","volume":"75","author":"Kamiya","year":"2010","journal-title":"Urology"},{"issue":"3 Pt 1","key":"10.1016\/j.clgc.2025.102433_bib0033","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.juro.2007.05.029","article-title":"Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach","volume":"178","author":"Koopmans","year":"2007","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102433_bib0034","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bjc.1994.377","article-title":"Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis","volume":"70","author":"Sano","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2025.102433_bib0035","doi-asserted-by":"crossref","first-page":"586192","DOI":"10.3389\/fonc.2020.586192","article-title":"Revealing prognostic value of skeletal-related parameters in metastatic castration-resistant prostate cancer on overall survival: a systematic review and meta-analysis of randomized controlled trial","volume":"10","author":"Tong","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2025.102433_bib0036","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2025.102433_bib0037","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1002\/cam4.5640","article-title":"Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer","volume":"12","author":"Ke","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2025.102433_bib0038","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3389\/fonc.2020.00558","article-title":"Association of body composition with survival and treatment efficacy in castration-resistant prostate cancer","volume":"10","author":"Pak","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2025.102433_bib0039","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clnesp.2016.04.001","article-title":"Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel","volume":"13","author":"Cushen","year":"2016","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"10.1016\/j.clgc.2025.102433_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","article-title":"Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy","volume":"7","author":"Ohtaka","year":"2019","journal-title":"Prostate Int"},{"issue":"9","key":"10.1016\/j.clgc.2025.102433_bib0041","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","article-title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","volume":"28","author":"Bozzetti","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102433_bib0042","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12149-022-01716-w","article-title":"Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223","volume":"36","author":"Bauckneht","year":"2022","journal-title":"Ann Nucl Med"},{"issue":"17","key":"10.1016\/j.clgc.2025.102433_bib0043","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.ejca.2015.07.042","article-title":"High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting","volume":"51","author":"Antoun","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102433_bib0044","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/bjc.2017.149","article-title":"Subcutaneous adiposity is an independent predictor of mortality in cancer patients","volume":"117","author":"Ebadi","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102433_bib0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.juro.2018.01.069","article-title":"Subcutaneous fat distribution is a prognostic biomarker for men with castration resistant prostate cancer","volume":"200","author":"Lee","year":"2018","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102433_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122047","article-title":"Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.clgc.2025.102433_bib0047","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41391-021-00442-0","article-title":"Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis","volume":"25","author":"Lopez","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102433_bib0048","doi-asserted-by":"crossref","DOI":"10.53876\/001c.120988","article-title":"Prostate Cancer and obesity: current hypotheses and challenges","author":"Capodice","year":"2024","journal-title":"IJCCD"},{"issue":"4","key":"10.1016\/j.clgc.2025.102433_bib0049","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1158\/1940-6207.CAPR-10-0229","article-title":"Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis","volume":"4","author":"Cao","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"10.1016\/j.clgc.2025.102433_bib0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1055-9965.EPI-17-0144","article-title":"The obesity paradox in cancer-moving beyond BMI-Response","volume":"26","author":"Shachar","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.clgc.2025.102433_bib0051","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2967\/jnumed.122.265379","article-title":"Elevated body mass index is associated with improved overall survival in castration-resistant prostate cancer patients undergoing prostate-specific membrane antigen-directed radioligand therapy","volume":"64","author":"Hartrampf","year":"2023","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.clgc.2025.102433_bib0052","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41391-021-00418-0","article-title":"The obesity paradox in metastatic castration-resistant prostate cancer","volume":"25","author":"Martini","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"10.1016\/j.clgc.2025.102433_bib0053","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/bjc.2017.303","article-title":"Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer","volume":"117","author":"Demark-Wahnefried","year":"2017","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.clgc.2025.102433_bib0054","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1002\/cncr.29472","article-title":"Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102433_bib0055","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41391-021-00346-z","article-title":"Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer","volume":"24","author":"Algotar","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clgc.2025.102433_bib0056","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41598-020-79345-4","article-title":"Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Burton","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.clgc.2025.102433_bib0057","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2015.07.026","article-title":"The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer","volume":"367","author":"Heidegger","year":"2015","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.clgc.2025.102433_bib0058","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11912-024-01520-x","article-title":"Current trends and challenges of microbiome research in prostate cancer","volume":"26","author":"Trecarten","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.clgc.2025.102433_bib0059","first-page":"202","article-title":"Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects","volume":"32","author":"Fusco","year":"2024","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102433_bib0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/03008916241236279","article-title":"Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey","volume":"110","author":"Valsecchi","year":"2024","journal-title":"Tumori"},{"issue":"24","key":"10.1016\/j.clgc.2025.102433_bib0061","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.3390\/cancers16244286","article-title":"The effect of resistance and\/or aerobic training on quality of life, fitness, and body composition in prostate cancer patients-a systematic review and meta-analysis","volume":"16","author":"Kempin","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:09:23Z","timestamp":1770671363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001338"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102433","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Health and Body Composition as Predictive and Prognostic Markers in Metastatic Castration-resistant Prostate Cancer: A Meet-URO Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102433"}}